German site
Pharmanovia Leadership Update
- Amit Patel and Sagar Patel to succeed James Burt as Joint CEOs
- Zubair Javeed appointed CFO, replacing interim CFO, David Murray
FOR IMMEDIATE RELEASE – BASILDON, UK, 10th APRIL 2025
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has confirmed that effective today, CEO, James Burt, is stepping down as CEO.
Founder, Amit Patel and Chief Operating Officer, Sagar Patel will assume the role of Joint-CEO, effective immediately. Amit and Sagar have a strong track record leading teams and provide important continuity as we enter a new phase of growth.
Amit founded Pharmanovia in 2013 and has played a critical role over recent years in diversifying Pharmanovia’s portfolio to incorporate more early-stage assets. Sagar joined Pharmanovia as Chief Operating Officer in 2022, bringing with him over 25 years’ experience in organisations including GSK and Fresenius Kabi.
In separate news, Zubair Javeed has joined Pharmanovia as its new Chief Financial Officer. Zubair has over 30 years’ experience steering finance functions for prominent global organisations. Previously, Zubair served as CFO at Ansell for six years before his resignation in October 2024, where he played a pivotal role in driving sustainable growth and a proven ability managing financial strategies that fuel organisational success. Zubair will succeed interim CFO David Murray who is retiring. David will continue with the organisation for a short period to ensure a seamless handover of responsibilities.
Guido Oelkers, Chair, Pharmanovia’s Advisory Board commented: “James has been instrumental in guiding this company through a significant period of growth that has seen us pivot to a lifecycle management company and enter the exciting world of novel medicines. We thank him for his leadership and commitment to Pharmanovia.
“In Amit and Sagar we have two seasoned executives who we are confident will lead us successfully into our new phase of growth.
“We would also like to take this opportunity to welcome Zubair as CFO and to thank David, our interim CFO, who has been instrumental in building a leading finance team to support our growth during a transformative period.”
-ends-
Notes to editors
For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
07912887250 / communications@pharmanovia.com
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.
With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.